Radiofrequency ablation is recommended for inclusion into benefit catalogue with restrictions for patients with metastatic spinal lesions in Austria

28

Jul 2017

The Ludwig Boltzmann Institute – Health Technology Assessment (LBI-HTA) has published results of systematic literature review of evidence in relation to efficacy and safety of radiofrequency ablation for patients with metastatic spinal lesions. 

The aim of this assessment was to define whether radiofrequency ablation with or without vertebroplasty (or other add-on therapies) is more effective and safe concerning pain, health-related quality of life and complications in comparison with standard of care. Within the systematic literature review 4 prospective and 5 retrospective single-arm studies were identified and were subsequently included into analysis.

However, potency of upcoming evidence was also considered. Thus, there are three ongoing studies:

  • Patients registry (STAR tumor ablation system (NCT02419703)
  • Combination of radiofrequency ablation and vertebroplasty (ChiCTR-INR-16010135)
  • Combination of thermal ablation and stereotactic sine radiosurgery (NCT02713269)

Quality of evidence was considered as low. In conclusion, LBI-HTA recommended radiofrequency ablation of spinal metastatic lesions for inclusion in benefit catalogue with restrictions. Re-evaluation of current evidence situation is recommended to perform after 2021 due to completion of ongoing studies.

Available evidence indicates that radiofrequency ablation under certain conditions is effective and safe procedure for the treatment of patients with painful metastatic spinal lesions in whom alternative treatment was insufficient or contraindicated. The intervention should only be performed in specialized centers and, if possible, with collection patient records in relation to potential and rare adverse events in patient registry.

See full report in English here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more